MEET RAFAMINE. A NEW APPROACH TO THE TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS

DOI: https://doi.org/10.29296/25877305-2022-02-14
Issue: 
2
Year: 
2022

Professor E. Popova, MD I.M. Sechenov First Moscow State Medical University (Sechenov
University), Ministry of Health of Russia

The article provides up-to-date data on pharmacological effects, mechanism of action and results of clinical experience of the new antiviral drug Rafamin. Rafamin possesses an immuno-mediated antiviral and antibacterial effect and involved in the implementation of the immune response against both viruses and bacteria. The therapeutic efficacy of the drug according to the results of a multicenter placebo-controlled randomized clinical trial was manifested in a significant reduction in the duration of the disease (almost a day) and a 4-fold increase in the proportion of patients with recovery on the 3rd day of therapy compared with placebo. Rafamin possesses its own antibacterial effect, contributes to the prevention of bacterial complications of acute respiratory viral infections, and therefore is of clinical interest.
Keywords: 
Рафамин
противовирусное действие
антибактериальное действие
острая респираторная вирусная инфекция
лечение
профилактика осложнений

References: 
  1. Hayden F.G., Sugaya N., Hirotsu N. et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018; 379 (10): 913–23. DOI: 10.1056/NEJMoa1716197
  2. Nicholson K.G., Aoki F.Y., Osterhaus A.D. et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group [published correction appears in Lancet. 2000; 356 (9244): 1856]. Lancet. 2000; 355 (9218): 1845–50. DOI: 10.1016/s0140-6736(00)02288-1
  3. Pshenichnaja N.Ju., Bulgakov, V.A., L'vov N.I. i dr. Klinicheskaja effektivnost' umifenovira pri grippe i ORVI (issledovanie ARBITR). Ter arh. 2019; 91 (3): 56–63 [Pshenichnaya N.Y., Bulgakova V.A., Lvov N.I. et al. Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR). Ter arkh. 2019; 91 (3): 56–63 (in Russ.)]. DOI: 10.26442/00403660.2019.03.000127
  4. Pshenichnaja N.Ju., Bulgakova V.A., Volchkova E.V. i dr. Obzor tekuschih i perspektivnyh napravlenij protivovirusnoj terapii grippa i ostryh respiratornyh virusnyh infektsij v Rossii. Ter arh. 2019; 91 (11): 105–9 [Pshenichnaya N.Y., Bulgakova V.A., Volchkova E.V. et al. Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia. Ter arkh. 2019; 91 (11): 105–9 (in Russ.)]. DOI: 10.26442/00403660.2019.11.000454
  5. Immunomodulators Market Analysis, By Product (Immunosuppressants, Immunostimulants, Antibodies), By Application (Oncology, Respiratory, HIV, Others), Forecast To 2027. Accessed February 14, 2022. URL: https://www.reportsanddata.com/report-detail/immunomodulators-market
  6. Shul'djakov A.A. i dr. Novye vozmozhnosti terapii ORVI u detej. Voprosy prakticheskoj pediatrii. 2015; 10 (5): 21–8 [Shul’dyakov A.A. et al. New possibilities in therapy of acute respiratory viral infections in children. Voprosy prakticheskoi pediatrii. 2015; 10 (5): 21–8 (in Russ.)].
  7. Instruktsija po meditsinskomu primeneniju preparata Rafamin. Accessed November 22, 2021 [Instruktsiya po meditsinskomu primeneniyu preparata Rafamin. Accessed November 22, 2021 (in Russ.)]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e72e07e8-22a4-4930-a101-c3de9359de88&t%22
  8. Tejmurazov M.G., Petrova N.V., Karelina E.A. i dr. Doklinicheskoe izuchenie effektivnosti novogo immunotropnogo preparata pri lechenii sal'monelleznoj infektsii. Bjulleten' sibirskoj meditsiny. 2021; 20 (2): 95–101 [Teymurazov M.G., Petrova N.V., Karelina E.A. et al. Nonclinical study of the new immunotropic drug effectiveness in salmonella infection treatment. Bulletin of Siberian Medicine. 2021; 20 (2): 95–101 (in Russ.)]. DOI: 10.20538/1682-0363-2021-2-95-101
  9. Petrova N.V., Emel'janova A.G., Tarasov S.A. i dr. Rezul'taty doklinicheskogo issledovanija effektivnosti eksperimental'nogo preparata na osnove tehnologicheski obrabotannyh antitel na modeljah grippa i smeshannoj virusno-bakterial'noj infektsii. Patogenez. 2020; 18 (4): 55–63 [Petrova N.V., Emelianova A.G., Tarasov S.A., et al. Efficacy of an experimental drug based on technologically processed antibodies in models of influenza infection and secondary bacterial pneumonia: Results of a preclinical study. Patogenez = Pathogenesis. 2020; 18 (4): 55–63 (in Russ.)]. DOI: 10.25557/2310-0435.2020.04.55-63
  10. Hamitov R.F., Nikiforov V.V., Zajtsev A.A. i dr. Otsenka effektivnosti i bezopasnosti kompleksnogo protivovirusnogo preparata na osnove antitel v terapii vzroslyh bol'nyh ostroj respiratornoj virusnoj infektsiej. Ter arh. 2022; 94 (1): 83–93 [Khamitov R.F., Nikiforov V.V., Zaitsev A.A. et al. Evaluation of the efficacy and safety of a complex antibody-based antiviral drug in the treatment of adult patients with acute respiratory viral infection. Ter arkh. 2022; 94 (1): 83–93 (in Russ.)]. DOI: 10.26442/00403660.2022.01.201345
  11. Zaharova I.N., Cheburkin A.V., Malinovskaja V.V. i dr. Znachenie sistemy interferonov v formirovanii immunnogo otveta u detej s ostrymi respiratornymi virusnymi infektsijami. Voprosy prakticheskoj pediatrii. 2009; 4 (5): 38–45 [Zakharova I.N., Cheburkin A.V., Malinovskaya V.V. et al. The significance of the interferon system for formation of the immune response in children with acute respiratory viral infections. Voprosy prakticheskoi pediatrii. 2009; 4 (5): 38–45 (in Russ.)].
  12. Tarasov S.A., Gorbunov E.A., Don E.S. et al. Insights into the Mechanism of Action of Highly Diluted Biologics. J Immunol. 2020; 205 (5): 1345–54. DOI: 10.4049/jimmunol.2000098
  13. Kramar'ov S.O., Zakordonets' L.V. Dosvid zastosuvannja preparatu «Ergoferon» u ditej z gostrimi respiratornimi virusnimi infektsijami. Sovremennaja pediatrija. 2014; 8 (64): 1–4 [Kramar’ov S.O., Zakordonets’ L.V. Dosvid zastosuvannya preparatu «Ergoferon» u ditei z gostrimi respiratornimi virusnimi infektsiyami. Sovremennaya pediatriya. 2014; 8 (64): 1–4 (in Ukraine)].
  14. Gorelov A.V., Geppe N.A., Blohin B.M. i dr. Vlijanie immunomodulirujuschej terapii na techenie ostryh respiratornyh infektsij virusnoj etiologii: metaanaliz klinicheskih issledovanij effektivnosti i bezopasnosti preparata Ergoferon v lechenii grippa i drugih ostryh respiratornyh virusnyh infektsij. Voprosy prakticheskoj pediatrii. 2021; 16 (4): 83–97 [Gorelov A.V., Geppe N.A., Blokhin B.M. et al. Impact of immunomodulation therapy on the course of acute viral respiratory infections: a meta-analysis of clinical trials assessing the efficacy and safety of Ergoferon in the treatment of influenza and other acute respiratory viral infections. Voprosy prakticheskoi pediatrii. 2021; 16 (4): 83–97 (in Russ.)]. DOI: 10.20953/1817-7646-2021-4-83-97
  15. Geppe N.A., Zaplatnikov A.L., Kondjurina E.G. i dr. Effektivnost' i bezopasnost' primenenija Anaferona detskogo i Anaferona dlja profilaktiki i lechenija grippa i drugih ostryh respiratornyh virusnyh infektsij: sistematicheskij obzor i metaanaliz. RMZh. Meditsinskoe obozrenie. 2021; 5 (5): 335–47 [Geppe N.A., Zaplatnikov A.L., Kondyurina E.G. et al. Efficacy and safety of Anaferon for children and Anaferon for the prevention and treatment of influenza and other acute respiratory viral infections: systematic review and meta-analysis. Russian Medical Inquiry. 2021; 5 (5): 335–47 (in Russ.)]. DOI: 10.32364/2587-6821-2021-5-5-335-347
  16. Haitov R.M. Immunologija: uchebnik. 4-e izd., pererab. i dop. M.: GEOTAR-Media, 2021; 520 s. [Khaitov R.M. Immunologiya: uchebnik. 4-e izd., pererab. i dop. M.: GEOTAR-Media, 2021; 520 s. (in Russ.)]. DOI: 10.33029/9704-6398-7-IMM-2021-1-520
  17. Blander J.M. The comings and goings of MHC class I molecules herald a new dawn in cross-presentation. Immunol Rev. 2016; 272 (1): 65–79. DOI: 10.1111/imr.12428
  18. Faivre V., Lukaszewicz A.-C., Payen D. Downregulation of blood monocyte HLA-DR in ICU patients is also present in bone marrow cells. PLoS One. 2016; 11 (11): 15. DOI: 10.1371/journal.pone.0164489
  19. Zhu M., Dai J., Wang C. et al. Fine mapping the MHC region identified four independent variants modifying susceptibility to chronic hepatitis B in Han Chinese. Hum Mol Genet. 2016; 25 (6): 1225–32. DOI: 10.1093/hmg/ddw003